Оценка эффективности доклинической диагностики болезни Паркинсона методом "затраты-полезность"

Denisova, Irina and Chubarova, Tatiana and Bogatova, Irina and Vartanov, Sergey and Kucheryanu, Valerian and Polterovich, Victor and Tourdyeva, Natalia and Shakleina, Marina (2020): Оценка эффективности доклинической диагностики болезни Паркинсона методом "затраты-полезность".

Abstract

Neurodegenerative diseases, Parkinson disease being an example, set challenges to modern societies both in terms of premature deaths and resources spent on treatment of the diseases. Prevention and early diagnostics in particular, are potential directions towards higher economic efficiency of healthcare interventions in this area. We suggest a way to modify the cost-utility approach to evaluation of economic efficiency of an early diagnostics method of Parkinson disease (PD) at the laboratory stage of the diagnostics method. The lack of detailed understanding of the early testing group selection and composition are the major challenges to economic evaluation here. In particular, we consider the approach to diagnose PD at the prodromal stage suggested by Ugrumov 2020. The early diagnostics at the prodromal stage, accompanied by neuroprotective therapy of those identified at high risk of PD, allows postponing PD development for later years. The innovative approach implies saving both direct and indirect costs of PD treatment in comparison with traditional approach but adds costs of testing for the high risk of PD. The latter component may be non-trivial depending on the rules of selection into the group of tested. We suggest a way to modify the cost-utility evaluation procedure so that to take this uncertainty into account. We formulate the economic efficiency condition of the early diagnostics method in terms of the minimal probability of PD in the tested group and estimate the probability based on the Russian data. The latter sets the important threshold for innovative technology when moving from the laboratory into the clinical stage.

• Item Type: MPRA Paper
• English Title: Estimating economic efficiency of preclinical diagnostics of Parkinson disease with cost-utility approach
• Language: Russian
• Keywords: Economic efficiency in healthcare, Parkinson disease, early diagnostics, cost-utility approach
• Subjects: H - Public Economics > H4 - Publicly Provided Goods > H43 - Project Evaluation ; Social Discount Rate; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health

References

Воробьев П.А., Авксентьева М.В., Юрьев А.С.,Сура М.В. Клинико-экономический анализ. – М.:Ньюдиамед, 2004. – 404 с.

Белоусов Д.Ю., Афанасьева Е.В. Фармакоэкономический анализ применения прамипексола пролонгированного действия в режиме монотерапии на ранних стадиях болезни Паркинсона // Качественная клиническая практика, 2015, № 1. С. 53-64

Гончарова З.А., И.В. Черникова, Е.А. Рабаданова, Х.И. Хадзиева. Современные аспекты эпидемиологии и досимптомной диагностики болезни Паркинсона \\ Медицинский вестник Юга России, 2014

Левин О. С. Клиническая эпидемиология болезни Паркинсона. В кн.: Болезнь Паркинсона и расстройства движений: рук. для врачей: по матер. II Нац. конгресса. Под ред. С. Н. Иллариошкина, О. С. Левина. М., 2011; с. 5–9.

Левин О.С., Васенина Е.Е., Ганькина О.А. (2015) Эффективность Сталево в лечении больных болезнью Паркинсона с моторными флуктуациями (клинико-фармакоэкономический анализ) //Современная терапия в психиатрии и неврологии. № 1. С. 16-23

Стародубов В.И., Ефремова Т.А., Коробов Н.В., Лошаков Л.А. Стандарты медицинской помощи в системе здравоохранения Российской Федерации: состояние и перспективы // Здравоохранение Российской Федерации. 2015; 59 (4): 4—9.)

Страчунская Паркинсонизм: оптимизация терапии на основе многокритериального анализа фармакоэпидемиологических и фармакоэкономических показателей. Дис на соис. степени д.м.н., М.,2008

Шиндряева 2011 Фармакоэкономический анализ ведения пациентов с болезнью Паркинсона. Пермский медицинский журнал. Том XXVIII номер 4 c 63-68

Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Дисконтирование при проведении фармакоэкономических исследований. // Фармакоэкономика. 2009; №4: c.10-13

Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Фамакоэкономический анализ лечения болезни Паркинсона // Медицинский Альманах, №3(12), сентябрь 2010, с. 193-197

Afentou Nafsika, Johan Jarl, Ulf‐G Gerdtham, Sanjib Saha Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review/ Moving disorders. Clinical Practice. Volume 6, Issue 4, April 2019 Pages 282-290

Beitz, Janice M. Parkinson's disease: a review// Frontiers in Bioscience S6, 65-74, January 1, 2014

Bohingamu Mudiyanselage Shalika, Jennifer J. Watts, Julie Abimanyi-Ochom, Lisa Lane, Anna T. Murphy, Meg E. Morris, and Robert Iansek . Cost of Living with Parkinson's Disease over 12 Months in Australia: A Prospective Cohort Study // Parkinsons Dis. 2017

Bovolenta Tânia M., Sônia Maria Cesar de Azevedo Silva, Roberta Arb Saba, Vanderci Borges, Henrique Ballalai Ferraz, Andre C. Felicio (2017). Systematic Review and Critical Analysis of Cost Studies Associated with Parkinson’s Disease // Parkinson’s Disease. Volume 2017, Article ID 3410946, 11 pages

Brouwer Werner , Ben van Hout, Frans Rutten (2000). A Fair Approach to Discounting Future Effects: Taking a Societal Perspective // Journal of Health Services Research & Policy Volume: 5 issue: 2, page(s): 114-118

Céu M, Coloma J. Health economics and cost of illness in Parkinson's disease. Mov Disord 2013; 8(1): 6– 9.

Fann Jean Ching-Yuan, Kai-Chieh Chang, Amy Ming-Fang Yen, Sam Li-Sheng Chen, Sherry Yueh-Hsia Chiu, Hsiu-His Chen, Horng-Huei Liou (2020). Cost-Effectiveness Analysis of Deep Brain Stimulation for Parkinson Disease in Taiwan World Neurosurgery Volume 138 June 2020, Pages e459-e468

Findley LJ, Wood E, Lowin J, Roeder C, Bergman A, Schifflers M. The economic burden of advanced Parkinson's disease: an analysis of a UK patient dataset. J Med Econ 2011; 14(1): 130– 139.

Gosse S.D. (2008) Assessing Cost effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Review of Pharmacoeconomics and Outcomes Research (Vol. 8, Issue 2), 165-178

Jun-Xiu Yang, Lei Chen, "Economic Burden Analysis of Parkinson’s Disease Patients in China", Parkinson’s Disease, vol. 2017, Article ID 8762939, 7 pages, 2017. https://doi.org/10.1155/2017/8762939

Hoehn M.M., Yahr M.D. (1998). Parkinsonism: onset, progression, and mortality. 1967 // Neurology. 50(2):318 -334

Kim A, Nigmatullina R, Zalyalova Z, Soshnikova N, Krasnov A, Vorobyeva N, Georgieva S, Kudrin V, Narkevich V, Ugrumov M. Upgraded methodology for the development of early diagnosis of Parkinson's Disease based on searching blood markers in patients and experimental models. Mol Neurobiol. 2019;56(5):3437-3450. doi:10.1007/s12035-018-1315-2.

Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V. & Jain, A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord.28, 311–318 (2013).

Muangpaisan W, Mathews A, Hori H, et al. A systematic review of the worldwide prevalence and incidence of Parkinson’s disease. J Med Assoc Thai 2011; 94 (6): 749–55.

Muñoz David A., Mehmet Serdar Kilinc, Harriet B. Nembhard, Conrad Tucker, Xuemei Huang (2017). Evaluating the cost-effectiveness of an early detection of Parkinson's disease through innovative technology // The Engineering Economist, 62:2, 180-196.

National Institute for Health and Care Excellence (UK). Parkinson’s disease in adults: diagnosis and management. London: National Institute for Health and Care Excellence (UK); 2017 Jul. (NICE Guideline, No. 71.) Appendix F, Full health economics report. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535840/

Neumann P.J. (2005) Using Cost-Effectiveness Analysis to Improve Healthcare. Oxford University Press, NY, USA Siderowf A., B. Ravina, H. A. Glick. Preference-based quality-of-life in patients with Parkinson's disease. Neurology. 59(1):103-108, 2002.

Tinelli Michela, Panos Kanavos, Federico Grimaccia (2016). Еhe value of early diagnosis and treatment in Parkinson’s disease. A literature review of the potential clinical and socioeconomic impact of targeting unmet needs in Parkinson’s disease. LSE

von Campenhausen S, Winter Y, Silva AR (2010) Costs of illness and care in Parkinson's Disease: An evaluation in six countries, Eur Neuropsychopharmacol, 21:180–91

Ugrumov M. Development of early diagnosis of Parkinson's disease: illusion or reality?. CNS Neurosci Ther. 2020;00:1–13. doi: 10.1111/cns.13429

Zhao YJ, Wee HL, Chan YH, et al. (2010). Progression of Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times // Moving Disorders. 25:710–716.